Leerink Swann Downgrades Fluidigm, Noting Company's Shares May Take 'A Breather' | GenomeWeb

NEW YORK (GenomeWeb News) – Leerink Swann today downgraded Fluidigm to Market Perform, saying the company "could take a breather in the near term" after a 30 percent spike in its stock since the start of the year.

In lowering Fluidigm from a previous Outperform rating, analyst Dan Leonard added that he sees "better risk/reward" in Genomic Health and Luminex.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.

Mar
02
Sponsored by
VelaDx

This online seminar will highlight recent advances in the use of next-generation sequencing to detect drug-resistant mutations in patients with HIV or HCV.